The Scottish and Manchester randomised trial of neo-adjuvant chemotherapy for advanced cervical cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/85473
Title:
The Scottish and Manchester randomised trial of neo-adjuvant chemotherapy for advanced cervical cancer.
Authors:
Symonds, R P; Habeshaw, T; Reed, N S; Paul, J; Pyper, E; Yosef, H; Davis, J; Hunter, Robin D; Davidson, Susan E; Stewart, Alan L; Cowie, V; Sarkar, T
Abstract:
204 eligible patients were entered into a multicentre randomised trial of neo-adjuvant chemotherapy prior to radical radiotherapy. The aim of this study was to assess whether there was any survival advantage in patients undergoing chemotherapy and radiotherapy compared with those given radiotherapy alone. Patients were aged up to 70 years, performance status 0-1/2, with bulky stage IIb, stage III or stage IVa squamous or adenosquamous carcinoma. Three cycles of methotrexate 100 mg/m2 and cisplatin 50 mg/m2 were given at 2-weekly intervals before radical radiotherapy. 104 eligible patients received the combination treatment and 100 radiotherapy only. The two arms of the study were well balanced for tumour and patient characteristics. The response rate to chemotherapy was 49%, 33% of patients in the radiotherapy (XRT) alone arm and 45% of the combination arm were clinically free of tumour at the end of treatment. The median follow-up for surviving patients is 5.4 years (range: 11 months-8 years) and 84% have been followed-up for more than 4 years. 134 patients have died (68 XRT only, 66 combined arm). The median survival RT alone was 111 weeks (95% confidence interval (CI) 72-151 weeks), combination arm 125 weeks (95% CI 79-170 weeks). The estimated death ratio is 0.79 (P = 0.19, 95% CI 0.56-1.12). The estimated 3-year survival is 40% (95% CI 30-50%) RT only compared with 47% (95% CI 37-57%) in the combination arm. Acute and late toxicity of radiotherapy was not increased by the addition of chemotherapy.
Affiliation:
Beatson Oncology Centre, Western Infirmary, Glasgow, UK. psymonds@uhl.trent.nhs.uk
Citation:
The Scottish and Manchester randomised trial of neo-adjuvant chemotherapy for advanced cervical cancer. 2000, 36 (8):994-1001 Eur. J. Cancer
Journal:
European Journal of Cancer
Issue Date:
May-2000
URI:
http://hdl.handle.net/10541/85473
DOI:
10.1016/S0959-8049(00)00034-4
PubMed ID:
10885603
Type:
Article
Language:
en
ISSN:
0959-8049
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorSymonds, R Pen
dc.contributor.authorHabeshaw, Ten
dc.contributor.authorReed, N Sen
dc.contributor.authorPaul, Jen
dc.contributor.authorPyper, Een
dc.contributor.authorYosef, Hen
dc.contributor.authorDavis, Jen
dc.contributor.authorHunter, Robin Den
dc.contributor.authorDavidson, Susan Een
dc.contributor.authorStewart, Alan Len
dc.contributor.authorCowie, Ven
dc.contributor.authorSarkar, Ten
dc.date.accessioned2009-11-05T17:01:07Z-
dc.date.available2009-11-05T17:01:07Z-
dc.date.issued2000-05-
dc.identifier.citationThe Scottish and Manchester randomised trial of neo-adjuvant chemotherapy for advanced cervical cancer. 2000, 36 (8):994-1001 Eur. J. Canceren
dc.identifier.issn0959-8049-
dc.identifier.pmid10885603-
dc.identifier.doi10.1016/S0959-8049(00)00034-4-
dc.identifier.urihttp://hdl.handle.net/10541/85473-
dc.description.abstract204 eligible patients were entered into a multicentre randomised trial of neo-adjuvant chemotherapy prior to radical radiotherapy. The aim of this study was to assess whether there was any survival advantage in patients undergoing chemotherapy and radiotherapy compared with those given radiotherapy alone. Patients were aged up to 70 years, performance status 0-1/2, with bulky stage IIb, stage III or stage IVa squamous or adenosquamous carcinoma. Three cycles of methotrexate 100 mg/m2 and cisplatin 50 mg/m2 were given at 2-weekly intervals before radical radiotherapy. 104 eligible patients received the combination treatment and 100 radiotherapy only. The two arms of the study were well balanced for tumour and patient characteristics. The response rate to chemotherapy was 49%, 33% of patients in the radiotherapy (XRT) alone arm and 45% of the combination arm were clinically free of tumour at the end of treatment. The median follow-up for surviving patients is 5.4 years (range: 11 months-8 years) and 84% have been followed-up for more than 4 years. 134 patients have died (68 XRT only, 66 combined arm). The median survival RT alone was 111 weeks (95% confidence interval (CI) 72-151 weeks), combination arm 125 weeks (95% CI 79-170 weeks). The estimated death ratio is 0.79 (P = 0.19, 95% CI 0.56-1.12). The estimated 3-year survival is 40% (95% CI 30-50%) RT only compared with 47% (95% CI 37-57%) in the combination arm. Acute and late toxicity of radiotherapy was not increased by the addition of chemotherapy.en
dc.language.isoenen
dc.subjectUterine Cervical Canceren
dc.subjectCancer Staging-
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshCarcinoma, Adenosquamous-
dc.subject.meshCarcinoma, Squamous Cell-
dc.subject.meshChemotherapy, Adjuvant-
dc.subject.meshCisplatin-
dc.subject.meshEngland-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshMethotrexate-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Staging-
dc.subject.meshScotland-
dc.subject.meshTreatment Outcome-
dc.subject.meshUterine Cervical Neoplasms-
dc.titleThe Scottish and Manchester randomised trial of neo-adjuvant chemotherapy for advanced cervical cancer.en
dc.typeArticleen
dc.contributor.departmentBeatson Oncology Centre, Western Infirmary, Glasgow, UK. psymonds@uhl.trent.nhs.uken
dc.identifier.journalEuropean Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.